Bailard’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bailard’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-36,000	Closed	-$1.65M	–	527
2017 Q4	$1.65M	Buy	36,000 +16,000	+80%	+$798K	0.1%	190
2017 Q3	$897K	Buy	+20,000	New	+$682K	0.07%	174
2017 Q2	–	Sell	-21,800	Closed	-$484K	–	305
2017 Q1	$484K	Buy	+21,800	New	+$468K	0.04%	211

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Bailard's JUNO Position: Q1 2018 in Review

Bailard sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 36,000 shares — an estimated $1.65M sold.

Bailard first reported a position in JUNO in Q1 2017 and held it in 3 quarters. The position peaked at $1.65M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Bailard reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Bailard sold 36,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.65M.
Bailard first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
Bailard's Juno Therapeutics, Inc. position peaked at $1.65M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Bailard's 13F filing for Q1 2018, filed 7 May 2018.